Altamira Therapeutics Ltd.

As of October 5, 2023, Altamira Therapeutics Ltd. is considered an attractive investment due to its undervaluation, reflected in a price-to-earnings ratio of 12.5 and strong performance compared to peers, having outperformed the Sensex by 5% over the past quarter.

As of October 1, 2023, there is insufficient technical data for Altamira Therapeutics Ltd. to determine a bullish or bearish outlook.

Altamira Therapeutics Ltd. is a biotechnology company focused on developing pharmaceutical products for inner ear disorders and mental health supportive care. It operates as a micro-cap company with a market cap of USD 0.57 million and reported a net profit loss of USD 4 million as of December 2018.

As of Jun 18, Altamira Therapeutics Ltd. has a market capitalization of 0.57 million, with net sales of 0.00 million and a net profit of -11.70 million over the latest four quarters. The company has shareholder's funds of 6.57 million and total assets of 8.65 million as of Dec 24.